These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
150 related articles for article (PubMed ID: 38921459)
1. Gut Microbiota and Sinusoidal Vasoregulation in MASLD: A Portal Perspective. Baffy G; Portincasa P Metabolites; 2024 Jun; 14(6):. PubMed ID: 38921459 [TBL] [Abstract][Full Text] [Related]
2. Breaking the barriers: the role of gut homeostasis in Metabolic-Associated Steatotic Liver Disease (MASLD). Benedé-Ubieto R; Cubero FJ; Nevzorova YA Gut Microbes; 2024; 16(1):2331460. PubMed ID: 38512763 [TBL] [Abstract][Full Text] [Related]
4. Potential mechanisms linking gut microbiota and portal hypertension. Baffy G Liver Int; 2019 Apr; 39(4):598-609. PubMed ID: 30312513 [TBL] [Abstract][Full Text] [Related]
5. NAD metabolic therapy in metabolic dysfunction-associated steatotic liver disease: Possible roles of gut microbiota. Lu X; Yang R; Chen Y; Chen D iScience; 2024 Mar; 27(3):109174. PubMed ID: 38405608 [TBL] [Abstract][Full Text] [Related]
6. Alteration of Gut Microbiota Composition in the Progression of Liver Damage in Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD). Zazueta A; Valenzuela-Pérez L; Ortiz-López N; Pinto-León A; Torres V; Guiñez D; Aliaga N; Merino P; Sandoval A; Covarrubias N; Pérez de Arce E; Cattaneo M; Urzúa A; Roblero JP; Poniachik J; Gotteland M; Magne F; Beltrán CJ Int J Mol Sci; 2024 Apr; 25(8):. PubMed ID: 38673972 [TBL] [Abstract][Full Text] [Related]
7. Disruption of gut barrier integrity and host-microbiome interactions underlie MASLD severity in patients with type-2 diabetes mellitus. Forlano R; Martinez-Gili L; Takis P; Miguens-Blanco J; Liu T; Triantafyllou E; Skinner C; Loomba R; Thursz M; Marchesi JR; Mullish BH; Manousou P Gut Microbes; 2024; 16(1):2304157. PubMed ID: 38235661 [TBL] [Abstract][Full Text] [Related]
8. Targeting the Adipose Tissue-Liver-Gut Microbiota Crosstalk to Cure MASLD. Gabbia D; De Martin S Biology (Basel); 2023 Nov; 12(12):. PubMed ID: 38132297 [TBL] [Abstract][Full Text] [Related]
9. The Lasting Effects of COVID-19 on the Progression of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD). Backer S; Khanna D Cureus; 2023 Sep; 15(9):e45231. PubMed ID: 37842470 [TBL] [Abstract][Full Text] [Related]
10. Nonalcoholic fatty liver disease and portal hypertension. Ryou M; Stylopoulos N; Baffy G Explor Med; 2020; 1():149-169. PubMed ID: 32685936 [TBL] [Abstract][Full Text] [Related]
11. Ileitis promotes MASLD progression via bile acid modulation and enhanced TGR5 signaling in ileal CD8 Zheng C; Wang L; Zou T; Lian S; Luo J; Lu Y; Hao H; Xu Y; Xiang Y; Zhang X; Xu G; Zou X; Jiang R J Hepatol; 2024 May; 80(5):764-777. PubMed ID: 38181823 [TBL] [Abstract][Full Text] [Related]
12. Origins of Portal Hypertension in Nonalcoholic Fatty Liver Disease. Baffy G Dig Dis Sci; 2018 Mar; 63(3):563-576. PubMed ID: 29368124 [TBL] [Abstract][Full Text] [Related]
14. A narrative review about cognitive impairment in metabolic Dysfunction-Associated liver disease (MASLD): Another matter to face through a holistic approach. Meroni M; Longo M; Paolini E; Dongiovanni P J Adv Res; 2024 Feb; ():. PubMed ID: 38369241 [TBL] [Abstract][Full Text] [Related]
15. COMPARISON OF GUT MICROBIOTA IN ALCOHOLIC AND METABOLIC-DYSFUNCION ASSOCIATED STEATOTIC LIVER DISEASE IN ANIMAL MODELS. Perlin CM; Longo L; Thoen RU; Uribe-Cruz C; Álvares-DA-Silva MR Arq Gastroenterol; 2024; 61():e23100. PubMed ID: 38511793 [TBL] [Abstract][Full Text] [Related]
16. Small intestinal bacterial overgrowth in obese patients with biopsy-confirmed metabolic dysfunction-associated steatotic liver disease: a cross-sectional study. Ortiz-López N; Madrid AM; Aleman L; Zazueta A; Smok G; Valenzuela-Pérez L; Poniachik J; Beltrán CJ Front Med (Lausanne); 2024; 11():1376148. PubMed ID: 38854668 [TBL] [Abstract][Full Text] [Related]
19. A gut microbiome signature for HIV and metabolic dysfunction-associated steatotic liver disease. Martínez-Sanz J; Talavera-Rodríguez A; Díaz-Álvarez J; Rosas Cancio-Suárez M; Rodríguez JM; Alba C; Montes ML; Martín-Mateos R; Burgos-Santamaría D; Moreno S; Serrano-Villar S; Sánchez-Conde M Front Immunol; 2023; 14():1297378. PubMed ID: 38162648 [TBL] [Abstract][Full Text] [Related]
20. Vitamin D and Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): Novel Mechanistic Insights. Aggeletopoulou I; Tsounis EP; Triantos C Int J Mol Sci; 2024 Apr; 25(9):. PubMed ID: 38732118 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]